SOLIRIS
SOLIRIS (Eculizumab) is an FDA-approved monoclonal antibody infusion therapy indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD) in adult patients. Each single-dose, preservative-free 1×30 mL vial contains Eculizumab, formulated for intravenous administration under professional supervision.
Eculizumab works by inhibiting complement protein C5, a component of the immune system that contributes to the destruction of red blood cells and tissue damage in complement-mediated diseases. This targeted therapy helps reduce hemolysis, prevent organ damage, and improve patient outcomes across multiple rare and severe disorders.
InfusionMed USA, based in Carrollton, Texas, supplies SOLIRIS and other specialty infusion therapies to hospitals, clinics, and infusion centers throughout Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain integrity, proper handling, and timely delivery for licensed healthcare providers.
Download Form